CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home Item
In Person at CNRIC: Hyperactivation of an RNA Binding Protein by Cancer-associated Mutations , homeApril 19, 11:00 a.m., Collaboratory, Children's National Research and Innovation Campus, Washington, D.C. | Daniel Dominguez, Ph.D., Assistant Professor, Pharmacology, UNC School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center (DC)
-
Home Item
In Person Seminar: Our Mass Spectrometry Screening Studies in the Mouse and Human Hearts in Health and Disease , homeApril 26, 2024, 11 a.m. | Anthony Gramolini, Ph.D., Professor, Physiology and Translational Biology and Engineering, Ted Rogers Centre for Heart Research, University of Toronto | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home Item
In Person Seminar: Regulation of Mitochondrial Parameters in Skeletal Muscle , homeMay 3, 2024, 11:00 a.m. | Glenn Rowe, Ph.D., Associate Professor of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research
-
Home Item
Planning the Future of Environmental Health Sciences , homeMay 9, 2024, 5:30 p.m. (Reception at 5 p.m.) | Rick Woychik, Ph.D., Director, National Institute of Environmental Health Sciences, National Institutes of Health | Maury Strauss Distinguished Public Lecture
-
Home Item
In Person Seminar: Flavors in Tobacco and Nicotine Products: Science-based Regulation , homeMay 10, 2024, 11:00 a.m. | Suchitra Krishnan-Sarin, Ph.D., Albert E. Kent Professor of Psychiatry, Yale School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and the Addiction Recovery Research Center
-
Home Item
CANCELLED: In Person Seminar: Sex Influences on Brain and Body: An Issue That is Here to Stay , homeMay 17, 2024, 11:00 a.m. | Larry Cahill, Ph.D., Professor, Neurobiology and Behavior, University of California, Irvine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research